5027results about "Hydroxy compound active ingredients" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

The invention discloses a hydroxytyrosol-ergothioneine eutectic crystal as well as a preparation method and application thereof, and belongs to the technical fields of medicines, foods, daily chemicals and the like. The invention provides a hydroxytyrosol-ergothioneine eutectic crystal. The X-ray powder diffraction pattern of the hydroxytyrosol-ergothioneine eutectic crystal has characteristic diffraction peaks at least corresponding to the positions where the 2 theta value is 4.21 degrees + / -0.2 degrees, 8.36 degrees + / -0.2 degrees, 12.29 degrees + / -0.2 degrees, 15.29 degrees + / -0.2 degrees, 19.40 degrees + / -0.2 degrees, 20.98 degrees + / -0.2 degrees, 23.12 degrees + / -0.2 degrees and 28.73 degrees + / -0.2 degrees. According to the hydroxytyrosol-ergothioneine eutectic, the melting point of hydroxytyrosol is increased, the hygroscopicity of hydroxytyrosol is remarkably reduced, and meanwhile the stability of hydroxytyrosol and ergothioneine is enhanced. In addition, after the ergothioneine hydroxytyrosol forms the eutectic crystal, the ergothioneine hydroxytyrosol can also play better anti-oxidation and anti-aging effects.

Building on U.S. Provisional Patent Application No. 63 / 693,803, paragraphs for 2D-to-3D conversion and [0023]-[0024] for secure content verification, the Matrix 3D AI Polygon Mesh Hash Key System revolutionizes transforming 2D content into secure, interactive 3D AR / VR assets. Integrating AI and LiDAR, it enables real-time 3D mesh generation with precise geospatial anchoring. Users can reshape 3D content instantly via natural language commands, enhancing interactivity. Quantum-resistant encryption, using AES-256 and CRYSTALS-Kyber, ensures robust asset security. The system excels in gaming, surveillance, content verification, military operations, space exploration, deepfake detection, and pharmaceutical research, offering unmatched precision and scalability. Its multi-stage rendering pipeline, powered by distributed AI-driven bots, supports efficient real-time 3D mesh generation, achieving 95% accuracy and 1 cm resolution. This AR / VR technology advancement transforms industries with scalable, secure solutions for interactive 3D content creation and management, setting a new standard for precision and versatility.

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

The invention discloses a probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as a preparation method and application thereof, and belongs to the field of biological medicines. The FCPs and hyaluronic acid (HA) are combined through non-covalent interaction, so that the hydrogel has colon targeting property and mucosal adhesion at the same time, and delivery of probiotics is facilitated. The hydrogel (HF) based on polysaccharide has good biocompatibility, and can be used for effectively encapsulating the probiotics and the natural products. Then, the PDA-TH NPs and BA are incorporated into the polysaccharide chain network of HF, and finally the BA-HF-PDAT targeted co-delivery system is constructed. The BA (at) HF-PDAT targeted co-delivery system can protect BA from serious gastrointestinal stress, and is jointly assembled with PDT-TH NPs to realize dual slow release of thymol (Thy), so that the treatment effect of BA and Thy is improved, and the BA (at) HF-PDAT targeted co-delivery system contributes to treatment of clostridium difficile infection (CDI).

The invention relates to an oral mucosa repairing medicine and a preparation method thereof, and belongs to the technical field of medicines, the medicine comprises barnacle peptide, salivary lactobacillus, resveratrol, a biphasic adhesion matrix, hydroxyapatite, vitamin B family and other components. The preparation method comprises the following steps: sequentially carrying out enzymolysis on barnacle gooseneck by pepsin and lumbrukinase to obtain barnacle peptide. The double-phase adhesion matrix comprises a water-phase matrix, an oil-phase matrix and lecithin; the water-phase matrix contains a chondroitin sulfate-chitosan quaternary ammonium salt compound, sodium alginate and other components; the oil-phase matrix comprises sesame oil, beeswax, a polylactic acid-glycolic acid copolymer and the like. According to the invention, barnacle peptide and salivary lactobacillus are prepared by adopting a special method and are matched with resveratrol for use, so that multi-target and multi-path promotion of oral mucosa repair can be realized; the chondroitin sulfate-chitosan quaternary ammonium salt compound is prepared through electrostatic and physical embedding, the chondroitin sulfate-chitosan quaternary ammonium salt compound is matched with other components to prepare the biphasic adhesion matrix, the biocompatibility is good, the adhesion is high, and the action time of a sustained-release drug is well prolonged.

The present invention provides information comprising at least one GSK-3 activator for use in the prevention and / or treatment of aging and aging-related conditions and diseases by increasing proteasome activity.

The invention relates to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating cognitive impairment of Parkinson's disease and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 180-220 parts of vinegar tortoise plastron, 90-110 parts of morinda officinalis, 90-110 parts of angelica sinensis, 90-110 parts of radix curcumae, 55-65 parts of rhizoma acori graminei, 55-65 parts of polygala tenuifolia, 180-220 parts of calcined dragon bone, 180-220 parts of caulis spatholobi and 1-3 parts of borneol. When all the medicines of the traditional Chinese medicine composition are combined, the compatibility of monarch, minister, assistant and guide is performed, so that the traditional Chinese medicine composition has the effects of tonifying kidney, promoting blood circulation, dispersing blood stasis and inducing resuscitation, can relieve cognitive impairments such as space navigation, space exploration, working memory and the like of a Parkinson's disease cognitive impairment model mouse caused by chronic hypoperfusion, and realizes the treatment effect on the Parkinson's disease cognitive impairment; good application prospects are realized.

The invention provides a hydroxytyrosol supramolecular compound and a preparation method and application thereof, and belongs to the technical field of cosmetics and biological medicine, the supramolecular compound comprises the following chemical components by mass: 0.01-10% of hydroxytyrosol, 2-45% of an amino acid compound, 2-20% of alpha hydroxy acid, 2-30% of urea, and 15-92% of water. The supramolecular compound can promote transdermal delivery of hydroxytyrosol and maintain the biological activity of hydroxytyrosol, shows high biocompatibility, and can be applied to product development in the antibacterial field, the regeneration field and the anti-aging field.

The invention belongs to the technical field of medical and mechanical combinations, and discloses a high-permeability and low-sensitivity ripdicaine wound patch and a preparation method thereof.The high-permeability and low-sensitivity ripdicaine wound patch comprises a wound patch body, and the wound patch body is prepared from, by mass, 0.1%-0.4% of sodium hyaluronate, 1.5%-3.5% of lidocaine, 1.5%-3.5% of prilocaine, 3%-10% of solvent, 0.5%-8% of emulsifier, 2%-10% of humectant, 0.1%-5% of soothing agent, 0.1%-1.5% of stabilizer, 0.1%-1% of thickener and the balance water. According to the present invention, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, and the total amount of the raw materials is 100%. And the anesthetic has the advantages of quick effect taking, low sensitivity, capability of resisting moist heat sterilization and good stability.

The invention relates to the technical field of exosomes, in particular to an exosome compound preparation with a hair growing effect and a preparation method of the exosome compound preparation. Comprising 12 to 22 parts of ginsenoside Rb1, 15 to 12 parts of biotin tripeptide-15, 8 to 15 parts of diammonium glycyrrhizinate, 50 to 70 parts of fish collagen peptide, 10 to 20 parts of soybean peptide, 0.5 to 4.5 parts of SHH protein, 0.5 to 2.5 parts of SMO inhibitor, 0.5 to 1.5 parts of HhSP protein, 5 to 10 parts of N-acetyl tyrosine, 0.1 to 2 parts of hyaluronic acid, 0.1 to 1 part of melatonin, 0.1 to 1 part of quercetin, 0.1 to 1 part of kaempferol, 0.1 to 1 part of tanshinone, 0.1 to 1 part of biotin and 0.1 to 1 part of vitamin A. The compound preparation is combined with exosomes from various sources, so that the hair papilla cell function is synergistically enhanced, and the damaged hair follicle structure is repaired.

The invention provides a gamma delta T cell preparation as well as a preparation method and application thereof, and belongs to the technical field of T cells. The liposome is prepared from the following raw materials in parts by weight: 15-20 parts of modified gamma delta T cell liposome, 1-3 parts of cell stimulating factors and 4-7 parts of culture medium freeze-dried powder, the modified gamma delta T cell lipidosome is prepared by embedding gamma delta T cells through lipidosome, coupling with acetylenic bond modified chitosan, and further mixing with MFAP4 protein and b4GALT1 protein. The culture medium freeze-dried powder is prepared by freeze-drying the culture medium in the engineering culture process of gamma delta T cells, and the cell stimulating factors are resveratrol and quercitrin. According to the gamma delta T cell preparation prepared by the invention, the survival ability and resistance of gamma delta T cells are improved, the anti-tumor activity of the gamma delta T cells is improved, and the gamma delta T cell preparation has relatively good antioxidant and anti-inflammatory effects, reduces the inhibition of inflammation on an immune system and has a very good treatment effect on pancreatic ductal adenocarcinoma.

The invention provides a traditional Chinese medicine gel patch for treating gouty arthritis and a preparation method thereof. The traditional Chinese medicine gel patch for treating gouty arthritis comprises at least a gel layer loaded with traditional Chinese medicine extracts; the traditional Chinese medicine extracts comprise the following raw materials: coix seed, phellodendron amurense, clematis root, radix scutellariae, atractylodes lancea, radix ophiopogonis, radix scutellariae, acer scutellariae, radix scutellariae, radix aconiti kusnezoffii, radix strychnii, frankincense, myrrh, angelica sinensis, safflower, cyathula root, radix paeoniae rubra, radix smilacis gracile, radix striatae, eucalyptus glomeratae, sophora flavescens, andrographis paniculatae, radix lobeliae, rhizoma coptidis, radix scutellariae, cassia twig, zanthoxylum bungeanum, and borneol; and a matrix of the gel layer comprises the following raw materials in parts by weight: silk fibroin, polyvinyl pyrrolidone, azido-polyethylene glycol-carboxylic acid, 1-ethynylcyclopropylcarboxylic acid, 2,5-dicarboxylic acid-3,4-ethylenedioxythiophene, and glycerol. The traditional Chinese medicine gel plaster of the present invention can achieve good therapeutic effects through percutaneous absorption.

The invention provides a preparation method and application of a mineral oral liquid containing fat-soluble vitamins, the fat-soluble vitamins are dissolved in an oil phase, then the oil phase is mixed with a water phase containing an emulsifier, and high-shear and high-pressure homogenization treatment is performed to obtain emulsified fat-soluble vitamins; dispersing the sweetening agent, the suspending aid, the pH regulator and the insoluble mineral substances to obtain a mixed solution; adding the emulsified fat-soluble vitamins and the flavor regulator into the mixed solution, adding water to a constant volume, and uniformly stirring to obtain a material solution; and canning the feed liquid, sealing, and sterilizing at high temperature to obtain the oral liquid. The fat-soluble vitamins in the oral liquid provided by the invention are small in particle size after being subjected to high-shear and high-pressure homogenization treatment, can tolerate high-temperature sterilization, is small in loss rate, good in dispersity and high in stability within the shelf life, and can maintain the actual content of the fat-soluble vitamins in the oral liquid and ensure the nutritional effect of the fat-soluble vitamins.

Embodiments of the present invention provide devices and methods for treating at least one condition by delivering an effective amount of energy and / or a compound to tissue in or surrounding the wall of a body lumen. The compound may include at least one of a gas, vapor, liquid, solution, emulsion, suspension, or combinations thereof of one or more materials. The delivered amount of compound and / or energy may be effective to injure or damage tissue, nerves, and / or nerve endings so as to alleviate symptoms of the condition.

The invention relates to the technical field of eutectic crystals, in particular to a lutein and mannitol eutectic crystal as well as a preparation method and application thereof, an XRD (X-Ray Diffraction) pattern of the eutectic crystal has characteristic diffraction peaks at least at positions where 2 theta angles are 9.71 degrees, 19.44 degrees, 20.4 degrees, 21.17 degrees, 22.07 degrees, 24.67 degrees, 25.32 degrees, 36.1 degrees, 40.39 degrees and 44.9 degrees, and error tolerance of + / -0.2 degrees exists; a characteristic endothermic peak exists at 163.7 DEG C in a DSC spectrum, and an error tolerance of + / -0.2 DEG C exists; the preparation method comprises the following steps: respectively dissolving mannitol and xanthophyll in water and absolute ethyl alcohol, mixing, carrying out high-temperature and high-pressure reaction, standing, crystallizing, filtering, spray-drying and grinding to obtain the eutectic crystal, and the eutectic crystal can be applied to cosmetics, health-care products, foods and medicines. The eutectic crystal provided by the invention has the advantage of good stability.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The invention provides a sarcandra glabra and honeysuckle compound preparation and a preparation method thereof, and during preparation, part of sarcandra glabra and honeysuckle are subjected to supercritical carbon dioxide extraction, volatile oil and medicine residues are collected, and the medicine residues and the rest of sarcandra glabra and honeysuckle are subjected to water extraction. A proper amount of beta-cyclodextrin is added into a water extract for inclusion, then concentration and supercritical extraction are performed to obtain volatile oil, and beta-cyclodextrin is used for inclusion, so that on the basis of increasing the efficacy of the volatile oil, the contents of chlorogenic acid and isofraxidin are increased, the curative effect of the medicine is enhanced, the synergistic effect of all components of the medicine is exerted, and the treatment effect of the medicine is improved. Menthol is clathrated with beta-cyclodextrin and then added into the paste powder to be mixed, granulated and tableted. On the premise of not influencing the dissolution of menthol and the direct stimulation effect on the throat, the effects of dispelling wind, clearing heat, relieving sore throat and relieving pain of the medicine are further enhanced, and meanwhile the problems that the quality of the product is not stable enough due to environmental change during storage, menthol is volatilized and is easy to crystallize, separate out and deteriorate are effectively solved.

The invention discloses a xanthophyll-nicotinamide eutectic crystal and a preparation method and application thereof, the eutectic crystal is formed by xanthophyll and nicotinamide according to the molar ratio of 1: 1 through intermolecular interaction of hydrogen bonds, Van der Waals force and the like, and the molecular formula is C46H62N2O3. According to the invention, xanthophyll and nicotinamide are combined through a co-crystal technology, a novel co-crystal with good water solubility and high bioavailability is formed, and the solubility and absorption efficiency of xanthophyll are significantly improved.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention relates to the technical field of plant essential oil products, and discloses a refreshing composition based on plant essential oil and a preparation method thereof.The method comprises the steps that an essential oil composition containing menthol, borneol, lime oil, patchouli oil, lavender oil, basil, pelargonium graveolens oil, clove oil and eucalyptus globulus leaf oil is prepared; constructing an ionic gel slow-release base layer; forming a plant source emulsifier composite two-phase system; and adding a light protection and anti-oxidation protection layer. According to the invention, the stability of the essential oil composition in an environment with change of illumination, temperature and humidity is remarkably improved, precise controlled release of essential oil components is realized, and the technical problems that a traditional essential oil product is easy to volatilize and poor in stability and different hydrophilic essential oil components are difficult to effectively load and release at the same time are solved.

The invention provides a composition for assisting in reducing blood sugar and improving insulin resistance and a preparation method of the composition, and relates to the technical field of functional fiber processing. The composition for assisting in reducing blood sugar and improving insulin resistance comprises the following raw materials in parts by weight: 10-15 parts of depolymerization type composite cereal fibers, 3-5 parts of konjac fibers, 3-5 parts of psyllium husk powder, 2-3 parts of sesame powder, 1-2 parts of xylitol and 0.1-0.5 part of vitamin C, the mass ratio of wheat fiber to corn fiber to sweet potato fiber to pea fiber in the depolymerization type composite grain fiber is (25-30): (35-40): (20-25): (10-15). The composition disclosed by the invention can assist in reducing blood sugar and has a good effect of improving insulin resistance.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.